Indeed, high levels of oncogenic c-MYC are found in 65% of human ovarian cancers [10,69] and are associated with the activation of stem cell-like potential [70,71,72,73,74,75], faster recurrence, platinum resistance, and the poor overall survival of ovarian cancer patients [76,77]. This evidence concerns the gene MYC and ovarian carcinoma.